51,611 Shares in Celcuity Inc. (NASDAQ:CELC) Bought by Wellington Management Group LLP

Wellington Management Group LLP acquired a new stake in Celcuity Inc. (NASDAQ:CELC - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 51,611 shares of the company's stock, valued at approximately $770,000. Wellington Management Group LLP owned 0.14% of Celcuity as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Samlyn Capital LLC increased its stake in Celcuity by 92.4% during the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company's stock worth $21,735,000 after acquiring an additional 637,190 shares during the last quarter. State Street Corp raised its stake in shares of Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company's stock valued at $16,512,000 after purchasing an additional 668,318 shares in the last quarter. Braidwell LP lifted its holdings in Celcuity by 71.2% during the 3rd quarter. Braidwell LP now owns 884,306 shares of the company's stock worth $13,185,000 after buying an additional 367,663 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Celcuity by 226.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company's stock valued at $3,305,000 after buying an additional 153,712 shares during the period. Finally, Driehaus Capital Management LLC grew its stake in Celcuity by 62.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company's stock worth $3,351,000 after buying an additional 78,525 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.

Celcuity Stock Up 3.8 %

Shares of NASDAQ:CELC traded up $0.46 during midday trading on Friday, reaching $12.46. 1,207,069 shares of the company were exchanged, compared to its average volume of 281,445. The stock has a fifty day simple moving average of $14.14 and a two-hundred day simple moving average of $15.40. The firm has a market cap of $462.64 million, a PE ratio of -4.77 and a beta of 0.74. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a fifty-two week low of $11.51 and a fifty-two week high of $22.19.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $27.00 target price on shares of Celcuity in a research note on Friday, November 15th. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They issued an "outperform" rating and a $27.00 price objective for the company. Needham & Company LLC reissued a "buy" rating and set a $23.00 target price on shares of Celcuity in a research note on Friday, November 15th. Finally, Stifel Nicolaus boosted their price target on shares of Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Celcuity has an average rating of "Buy" and an average target price of $29.17.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.